Pfizer’s chief scientific officer and president of R&D, Mikael Dolsten, has said he will step down from the role in the coming months, kicking off the search for a successor. Dolsten’s ...
2monon MSN
Pfizer (NYSE:PFE) announced Tuesday that its Chief Scientific Officer and President of Research & Development (R&D), Mikael ...
US pharmaceutical giant Pfizer on Tuesday said its chief scientific officer Mikael Dolsten, a key figure behind the ...
According to the group’s soon-to-depart chief scientific officer, Mikael Dolsten, Pfizer has a “robust pipeline” of three clinical and several preclinical candidates. While danuglipron has ...
7d
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...
As Rocket Pharmaceuticals welcomes Dr. Mikael Dolsten from Pfizer to its Board of Directors, it's valuable to understand the financial health and market position of Pfizer (NYSE: PFE), where Dr ...
"We're going to test that starting now in late January, when we're rolling out clinical trials comparing Omicron towards the current vaccine," Mikael Dolsten, Pfizer's chief scientific officer ...
The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...
"Our ability to stop living in fear is now within reach," Mikael Dolsten, Pfizer's chief scientific officer, told Insider. "This should really break the fear, reduce the tremendous burden on ...
Dr. Dolsten is an accomplished industry ... curing genetic disease,” said Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development. “I am excited to bring ...
As Rocket Pharmaceuticals welcomes Dr. Mikael Dolsten from Pfizer to its Board of Directors, it's valuable to understand the financial health and market position of Pfizer (NYSE: PFE), where Dr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback